A Study of LY3841136 in Overweight and Obese Participants
Completed · Phase 1 · NCT06345066
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $4.1M
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 96
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), LY3841136 (drug), Placebo (drug)
- Dates
- Started 2024-04-03; completion 2025-09-29
- Results posted
- Not yet
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
From ClinicalTrials.gov, last updated 2025-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $4.1M in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hugh A. Coleman, DO Family Medicine · Daytona Beach, FL
- Kathleen M. Doisy, MD Pediatrics · Columbia, MO
- Archie V. Bowie II, MD Student in an Organized Health Care Education/Training Program · Odessa, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $1.4M
- Covance Clinical Research LP Dallas $1.4M
- Fortrea Clinical Research Unit Inc $1.4M
- $360
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.